MiNK Therapeutics(INKT) Newsfilter·2025-03-04 12:30Company Overview - MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and other immune-mediated diseases [3] Upcoming Financial Results - The company will release its fourth quarter and year-end 2024 financial results before the market opens on March 18, 2025 [1] - MiNK executives will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide a corporate update [1] Conference Call Details - Dial-in numbers for the conference call include 646-307-1963 (New York) and 800-715-9871 (USA & Canada) [2] - A live webcast and replay of the conference call will be available on the company's Events & Presentations page [2]